Your browser doesn't support javascript.
loading
Allogeneic hematopoietic cell transplantation using fludarabine plus myeloablative busulfan and melphalan confers promising survival in high-risk hematopoietic neoplasms: a single-center retrospective analysis.
Edahiro, Taro; Kawase, Takakazu; Nagoshi, Hisao; Fujino, Keita; Toishigawa, Kayo; Miyama, Takahiko; Mino, Tatsuji; Yoshida, Tetsumi; Morioka, Takehiko; Hirata, Yuji; Noma, Mitsunori; Fujii, Teruhisa; Nishizawa, Masatoshi; Fukushima, Noriyasu; Ichinohe, Tatsuo.
Affiliation
  • Edahiro T; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
  • Kawase T; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
  • Nagoshi H; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
  • Fujino K; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
  • Toishigawa K; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
  • Miyama T; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
  • Mino T; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
  • Yoshida T; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
  • Morioka T; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
  • Hirata Y; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
  • Noma M; Division of Transfusion Medicine, Hiroshima University Hospital, Hiroshima, Japan.
  • Fujii T; Division of Transfusion Medicine, Hiroshima University Hospital, Hiroshima, Japan.
  • Nishizawa M; Next Generation Development of Genome and Cellular Therapy Program, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
  • Fukushima N; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
  • Ichinohe T; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
Hematology ; 26(1): 186-198, 2021 Dec.
Article in En | MEDLINE | ID: mdl-33594942
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Hematopoietic Stem Cell Transplantation / Hematologic Neoplasms / Transplantation Conditioning Type of study: Diagnostic_studies / Etiology_studies / Observational_studies Aspects: Patient_preference Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Hematology Journal subject: HEMATOLOGIA Year: 2021 Document type: Article Affiliation country:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Hematopoietic Stem Cell Transplantation / Hematologic Neoplasms / Transplantation Conditioning Type of study: Diagnostic_studies / Etiology_studies / Observational_studies Aspects: Patient_preference Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Hematology Journal subject: HEMATOLOGIA Year: 2021 Document type: Article Affiliation country: